Press Release

Walden and Burgess on FDA’s Draft Guidance Promoting New Treatments for Opioid Use Disorder


WASHINGTON, DC – House Energy and Commerce Committee Chairman Greg Walden (R-OR) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX) released the following statement after the Food and Drug Administration (FDA) issued draft guidance on new treatments for individuals with opioid use disorder (OUD).

“We appreciate the FDA’s efforts to be a willing partner in the collective fight to combat the opioid crisis. Encouraging the use of medication-assisted treatment (MAT) has the potential to really help stem the tide of this crisis. Paired with the House-passed H.R. 6, the SUPPORT for Patients and Communities Act, this is another important step forward and we urge the Senate to act. We know there is no single solution to stop this epidemic, but we are encouraged by the Trump Administration’s efforts to address the ‘crisis next door,’ and their all-encompassing approach to do so.”


Press Release